<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01663038</url>
  </required_header>
  <id_info>
    <org_study_id>119HPS10F</org_study_id>
    <nct_id>NCT01663038</nct_id>
  </id_info>
  <brief_title>Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination</brief_title>
  <official_title>Comparative Pharmacokinetics of Clopidogrel 75mg and Aspirin 100mg After Single Oral Administration as a Fixed Dose Combination Versus Separate Combination in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare pharmacokinetics between fixed-dose combination and
      separate combination of clopidogrel 75mg/aspirin 100mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of clopidogrel/acetylsalicylic acid</measure>
    <time_frame>Pre-dose, 0.33h, 0.67h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 10h, 12h, 24h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of clopidogrel/acetylsalicylic acid</measure>
    <time_frame>Pre-dose, 0.33h, 0.67h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 10h, 12h, 24h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Cmax of salicylic acid.</measure>
    <time_frame>Pre-dose, 0.33h, 0.67h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 10h, 12h, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess AUC of salicylic acid.</measure>
    <time_frame>Pre-dose, 0.33h, 0.67h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 10h, 12h, 24h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Clopidogrel and Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Copidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel and Aspirin separate combination, single dose</description>
    <arm_group_label>Clopidogrel and Aspirin</arm_group_label>
    <other_name>Clopidogrel: Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed dose combination of clopidogrel/Aspirin</intervention_name>
    <description>Fixed dose combination of clopidogrel/aspirin</description>
    <arm_group_label>Copidogrel</arm_group_label>
    <other_name>Coprigrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Clopidogrel and Aspirin</arm_group_label>
    <other_name>Aspirin: Astrix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy male volunteer aged 20 to 55, and within 20% of ideal body weight.

          -  Have not any congenital or chronic diseases and medical symptom.

          -  Appropriate subject for the study judging from examinations(interview, vital signs,
             12-lead ECG, physical examination, blood, urinalysis result on screening.

          -  Able to participate in the entire trial.

          -  Signed the informed consent form prior to study participation.

        Exclusion Criteria:

          -  Take metabolic enzyme inducing or inhibiting drugs like barbiturates within 28 days
             prior to the first IP administration.

          -  show evidence of acute disease within 28 days prior to the first IP administration.

          -  Have the medical history of bleeding symptom or bleeding disease

          -  Have the disease history(ex. Inflammatory intestinal disease, stomach or duodenum
             ulcer, liver and bowels disease, appendectomy except of gastrointestinal surgery
             history) that may influence on the absorption, distribution, metabolism and excretion
             of the drug.

          -  Have relevant hypersensitivity against drug or clinically significant allergic
             diseases except mild rhinitis that does not need medication.

          -  Have hypersensitivity reaction histories for Clopidogrel or aspirin.

          -  Have abnormal laboratory result. AST or ALT &gt; 1.25 times of upper limit/ Total
             bilirubin &gt; 1.5 times of upper limit/ PT, aPTT, BT over upper limit/ Platelet count
             &lt;150X10^9/L or &gt;350X10^9/L

          -  A drug abuse or a heavy caffeine consumer (more than 5cups per a day) or a heavy
             smoker (more than 10 cigarettes per a day) or a regular alcohol consumer(more than
             30g/day) or drinking within 7days prior to the first IP administration.

          -  Have a diet(Especially, grapefruit juice-within 7days prior to the first IP
             administration) that may influence on the absorption, distribution, metabolism and
             excretion of the drug(s).

          -  Have donated whole blood within 60 days prior to the first IP administration.

          -  Participated in the other clinical trials within 90days prior to the first IP
             administration.

          -  Take medicine which affect to this trial within 10 days prior to the first IP
             administration.

          -  Appropriate subject for the trial judging from principal investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JH Shon, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Pusan Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2012</study_first_posted>
  <last_update_submitted>August 10, 2012</last_update_submitted>
  <last_update_submitted_qc>August 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clopidogrel</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Combination</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

